These associations were even more pronounced among individuals with NAFLD (moderate-to-severe SLD) or advanced liver fibrosis, who demonstrated greater metabolic dysregulation, systemic inflammation, and CKM burden (Table 2). The gene discussed is CKM; the disease is Hepatic fibrosis.